Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

Cancer
Eric T WongJulian K Wu

Abstract

Methotrexate-based and alkylator-based chemotherapy regimens are associated with renal and bone marrow toxicities, which limit their use in patients with central nervous system (CNS) lymphomas. The authors report their experience with an immunochemotherapy regimen consisting of rituximab and temozolomide in patients with primary or metastatic CNS lymphoma. Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only. Patients were scheduled to receive 4 cycles of induction rituximab on Day 1 and temozolomide on Days 1-5 of a 28-day cycle. Thereafter, their treatment included a total of up to 8 maintenance cycles of temozolomide alone on Days 1-5 of a 28-day cycle. A gadolinium-enhanced magnetic resonance image of the head was obtained after every two cycles of treatment. All patients received rituximab without toxicity. Of the 4 patients who received induction temozolomide at doses > 150 mg/m(2) daily on...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L M DeAngelisU Kher
Nov 2, 1988·Journal of the National Cancer Institute·P McLaughlinF Cabanillas
Mar 4, 2000·Cellular and Molecular Neurobiology·P A Stewart
Apr 6, 2000·Journal of the National Cancer Institute·M ReniE Villa
Apr 13, 2000·Neurology·U HerrlingerM Weller
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A DavisR Levy
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Sep 21, 2002·Journal of Neuro-oncology·Keith A Lerro, Jill Lacy
Oct 24, 2002·Blood·James L RubensteinMarc A Shuman
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthUNKNOWN Minnie Pearl Cancer Research Network
Feb 1, 2002·Seminars in Oncology·David G MaloneyAndrea Rose

❮ Previous
Next ❯

Citations

Aug 13, 2013·Current Treatment Options in Oncology·Lakshmi Nayak, Tracy T Batchelor
Dec 22, 2004·Current Oncology Reports·Igor T Gavrilovic, Lauren E Abrey
Feb 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K FritschG Illerhaus
Jan 1, 2005·Current Opinion in Oncology·Khê Hoang-XuanCarole Soussain
Nov 16, 2005·The Neurologist·Amy A Pruitt, Myrna R Rosenfeld
Jul 14, 2006·Annals of the Rheumatic Diseases·R C ChouA M Reginato
Oct 3, 2012·Case Reports in Oncological Medicine·Hugo Ferro, Eduardo Parino
Mar 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leslie L MuldoonEdward A Neuwelt
Jan 10, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew J WieduwiltJames L Rubenstein
Feb 5, 2005·Onkologie·Ulrich HerrlingerUNKNOWN Centers for Neuro-Oncology and Lymphoma, University of Tubingen, Germany
Jul 27, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M SantistebanO Fernández Hidalgo
Jul 11, 2006·Ocular Immunology and Inflammation·Robert B NussenblattUNKNOWN CNS and Ocular Lymphoma Workshop Group
Jun 5, 2012·Leukemia & Lymphoma·Lakshmi NayakUNKNOWN North American Brain Tumor Consortium
Oct 27, 2006·Leukemia & Lymphoma·Kieron Dunleavy, Wyndham H Wilson
Oct 23, 2012·Expert Review of Neurotherapeutics·Niklas SchäferUlrich Herrlinger
Mar 23, 2011·Expert Review of Anticancer Therapy·Ahmad S Halwani, Brian K Link
Nov 9, 2005·Expert Review of Neurotherapeutics·Jennifer I Stern, Jeffrey J Raizer
May 12, 2007·Expert Review of Anticancer Therapy·Elizabeth Gerstner, Tracy Batchelor
Aug 24, 2006·Expert Review of Anticancer Therapy·Nicole Mutter, Roger Stupp
Mar 31, 2012·Clinical Oncology : a Journal of the Royal College of Radiologists·E Gallop-Evans
Oct 28, 2009·Clinical Lymphoma & Myeloma·Emanuela ChimientiUmberto Tirelli
Mar 21, 2007·American Journal of Clinical Pathology·Justine R SmithRita M Braziel
Mar 22, 2005·European Journal of Haematology·Markus DietleinRoland Schnell
Oct 22, 2005·Annals of Neurology·Janet W de BeukelaarJan W Gratama
Aug 22, 2013·Blood·James L RubensteinPatrick Treseler
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carole SoussainUNKNOWN Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Jan 8, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian L BurnetteThomas E Witzig
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leslie L MuldoonEdward A Neuwelt
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James L RubensteinLawrence D Kaplan
Nov 28, 2016·Hematology/oncology Clinics of North America·Julia Carnevale, James L Rubenstein
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian Grommes, Lisa M DeAngelis
Apr 28, 2017·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Mashya AbbassiVictor Yazbeck
Nov 14, 2018·Neuro-oncology·Christian GrommesTracy T Batchelor
Nov 11, 2005·Current Opinion in Neurology·Scott R Plotkin
Sep 24, 2013·Expert Review of Anticancer Therapy·Saurabh DahiyaManmeet S Ahluwalia
May 13, 2009·The Oncologist·Monica Sierra del RioKhê Hoang-Xuan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

© 2022 Meta ULC. All rights reserved